Spyre Therapeutics Reports Strong Phase 2 Data and Completes Enrollment in Key Trials — Spyre Therapeutics, Inc.

Event summary

Positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, showing best-in-class efficacy potential.
Completion of enrollment for the Phase 2 SKYWAY basket trial, with all three sub-studies over-enrolling on or ahead of schedule.
$1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, with expected runway into the second half of 2029.
Six proof-of-concept Phase 2 readouts expected in 2026, including data for rheumatoid arthritis (RA) sub-study in SKYWAY and SPY003 Part A data from SKYLINE in September.

The big picture

Spyre Therapeutics is positioning itself as a leader in next-generation immunology therapies, focusing on inflammatory bowel disease (IBD) and rheumatic diseases. The company's Phase 2 trials are critical for validating its combination therapy approach, which aims to deliver superior efficacy, safety, and convenience compared to existing treatments. With a strong cash position and multiple data readouts expected by the end of 2026, Spyre is poised to make significant strides in the competitive immunology space.

What we're watching

Clinical Efficacy: How the upcoming proof-of-concept data for SPY072 in rheumatoid arthritis will impact Spyre's broader immunology strategy.
Financial Runway: Whether Spyre can maintain its cash runway into 2029 amid increasing R&D expenses and clinical trial costs.
Combination Therapy Potential: The pace at which Spyre can advance its rational combinations in Part B of the SKYLINE trial to demonstrate best-in-class efficacy in IBD.